MARYLAND / RankWire.AI / – As pancreatic cancer remains one of the most aggressive and difficult-to-treat malignancies, the U.S. Food and Drug Administration has granted approval to Rasonque, also known as daraxonrasib, for select adults battling metastatic pancreatic adenocarcinoma. The agency approved the once-daily pill on August 26, 2026, offering a new targeted therapy option for patients. This approval applies to adults who have previously undergone at least one systemic treatment and includes those who are ineligible for multi-agent systemic therapies. The medication was developed by Revolution Medicines and specifically targets the RAS GTPase family.
The decision was based on data from RASolute 302, a Phase 3 trial that was randomized, open-label, and conducted across multiple centers involving 500 adult participants. All had metastatic pancreatic adenocarcinoma that had progressed following one prior systemic therapy. Researchers randomized 248 patients to receive daraxonrasib and 252 to a chemotherapy regimen selected by their physicians. Results showed a median overall survival of 13.2 months for those treated with daraxonrasib, compared to 6.7 months for patients on standard chemotherapy. The FDA reported a hazard ratio for death of 0.40.
In addition, progression-free survival was notably extended in the entire study population. Patients on daraxonrasib experienced a median progression-free survival of 7.2 months, while those on chemotherapy had 3.6 months. The objective response rate was 30% with daraxonrasib versus 11% with chemotherapy. These differences in overall survival, progression-free survival, and response rate were all statistically significant, reinforcing the drug’s potential benefit for patients whose metastatic disease has already required systemic intervention.
Targeted Therapy Interferes with RAS Signaling Pathway
Daraxonrasib acts as an inhibitor of RAS proteins, designed to hinder the active forms that promote tumor growth. Since RAS mutations are found in over 90% of pancreatic ductal adenocarcinomas, this targeted approach addresses a critical driver of the disease. The medication is administered orally at a recommended dose of 300 milligrams once each day, continuing until disease progression or unacceptable side effects occur. The approval encompasses metastatic pancreatic adenocarcinoma without requiring a specific RAS mutation in the prescribing information.
Safety data indicated that adverse events occurred in all patients treated with daraxonrasib during the Phase 3 trial. Grade 3 or higher adverse events were observed in 61.8% of the daraxonrasib group and 69.6% of those receiving chemotherapy. Treatment discontinuation related to adverse events was 1.2% for daraxonrasib and 11.2% for chemotherapy. Common side effects include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, edema, reduced appetite, and bleeding. The prescribing information also highlights several serious warnings and precautions.
Accelerated Review Processes and Regulatory Collaboration
Among the warnings are risks of skin and soft tissue toxicity, oral disorders, diarrhea, gastrointestinal perforation, and interstitial lung disease or pneumonitis. The label also cautions about embryo-fetal toxicity. The FDA expedited the review through multiple oncology programs, including Real-Time Oncology Review and the Commissioner’s National Priority Voucher pilot, and indicated that approval was granted approximately 6.5 months prior to the target date. Daraxonrasib received both Breakthrough Therapy and Orphan Drug designations.
The agency employed Project Orbis, facilitating collaboration with international regulators on oncology submissions. Health Canada participated in the review process, with European and Japanese agencies serving as official observers. The FDA noted that the application might still be under review in other jurisdictions. This approval marks the first authorization of Rasonque for Revolution Medicines within the U.S. patient population, with the key Phase 3 trial showing a median overall survival of 13.2 months versus 6.7 months with chemotherapy for previously treated metastatic pancreatic cancer patients.